Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

SAN CARLOS, Calif.–(BUSINESS WIRE)– #livebiotherapeuticproducts–Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for Siolta’s approach to developing live microbiome-based therapeutics. The funds raised in this round will support the further clinical development of Siolta’s lead product, STMC-103H, a defined-consortia Live Biothe
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks